Search Results

OncoQuest Pharmaceuticals Inc., (“OncoQuest”) a clinical-stage biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer, today announces the first patient enrolled in each of two investigator initiated clinical trials assessing the safety and efficacy of oregovomab in a previously treated recurrent ovarian cancer setting.

Quest PharmaTech Inc. (TSXV: QPT) (“Quest” or the “Company”) announces that clinical investigators working with OncoQuest Pharmaceuticals, Inc. (“OQP”) lead clinical candidate oregovomab, will be making two presentations as part of the American Society of Clinical Oncology (ASCO) conference proceedings

Quest PharmaTech Inc. (TSXV: QPT) announces that OncoQuest Pharmaceuticals, Inc., Seoul, South Korea (078590.KQ) (“OQP”) has begun dosing patients in the USA for the Phase 3 clinical trial of its immunotherapeutic drug candidate oregovomab.

OncoQuest Inc. announced the publication of two reports relating to the recently completed Phase 2 trial conducted in the US and Italy utilizing oregovomab, the Company’s lead investigational drug in frontline ovarian cancer.

OncoQuest Inc., a privately held, cancer immunotherapy company, has retained the services of IQVIA, a company formed through the merger of IMS Health and Quintiles, to manage OncoQuest’s planned Phase 3 clinical study in frontline ovarian cancer with the company’s lead product candidate, oregovomab, an anti-CA-125 antibody.

OncoQuest Inc. (“OncoQuest”), a privately held, cancer immunotherapy company, today announced the appointment of Dr. Eliel Bayever as Chief Medical Officer.

OncoQuest Inc., a privately held, cancer immunotherapy company announced that a Notice of Allowance was received from the U.S. Patent and Trademark Office for patent protection of the schedule of administration of our monoclonal anti-CA-125 antibody, mAb-B43.13, now known as oregovomab, in a specific schedule in combination with carboplatin and paclitaxel in Stage III-IV ovarian cancer patients.

Oncoquest today announced the signing of a collaborative agreement with TESARO to conduct a proof-of-concept clinical trial evaluating the combination of oregovomab with ZEJULA (niraparib) in the recurrent ovarian cancer setting.

Consideration is U.S.$10 million in Cash and U.S.$40 million in a Convertible Bond